WO2024033703 - AMORPHOUS SOLID DISPERSIONS COMPRISING NAPORAFENIB
National phase entry:
Publication Number
WO/2024/033703
Publication Date
15.02.2024
International Application No.
PCT/IB2023/000477
International Filing Date
09.08.2023
Title **
[English]
AMORPHOUS SOLID DISPERSIONS COMPRISING NAPORAFENIB
[French]
DISPERSIONS SOLIDES AMORPHES COMPRENANT DU NAPORAFÉNIB
Applicants **
NOVARTIS AG
Inventors
GRANER, Oliver
HARLACHER, Cornelius, Stephan
HOOTON, Jennifer, Claire
IYER, Raman
SETHURAMAN, Vijay
Priority Data
63/370,989
10.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2322 | |
| EPO | Filing, Examination, Granting | 12243 | |
| Japan | Filing, Examination, Granting | 2420 | |
| South Korea | Filing, Examination, Granting | 2462 | |
| USA | Filing, Examination, Granting | 5740 |
Total:
25,187
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition comprising N (3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4- yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, or a pharmaceutically acceptable salt thereof. The present invention also provides a process for preparing said pharmaceutical compositions for oral administration and methods of treatment with said pharmaceutical compositions.[French]
La présente invention concerne le domaine de la pharmacie, en particulier une composition pharmaceutique comprenant le N (3-(2-(2-hydroxyéthoxy)-6-morpholinopyridine-4-yl)-4-méthylphényl)-2- (trifluoromethyl)isonicotinamide, ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également un procédé de préparation desdites compositions pharmaceutiques pour administration orale et des méthodes de traitement faisant appel auxdites compositions pharmaceutiques.